- Trials with a EudraCT protocol (37)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
37 result(s) found for: Novel coronavirus.
Displaying page 1 of 2.
EudraCT Number: 2020-004695-18 | Sponsor Protocol Number: RES-Q-HR | Start Date*: 2020-12-02 | ||||||||||||||||||||||||||
Sponsor Name:Heinrich-Heine-University Düsseldorf | ||||||||||||||||||||||||||||
Full Title: Reconvalescent plasma/Camostat mesylate early in Sars-CoV-2 Q-PCR positive high risk individuals | ||||||||||||||||||||||||||||
Medical condition: The novel coronavirus designated SARS CoV-2, and the disease caused by this virus designated COVID-19. No treatment is available for early disease stages and non-hospitalized patients to date. This... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002008-19 | Sponsor Protocol Number: C4591044 | Start Date*: 2024-07-16 | |||||||||||||||||||||
Sponsor Name:BioNTech SE | |||||||||||||||||||||||
Full Title: An Interventional, Randomized, Active-Controlled, Phase 1/2/3 Study to Investigate the Safety, Tolerability, and Immunogenicity of BNT162b RNA-Based Vaccine Candidates in Covid-19 Vaccine–Experienc... | |||||||||||||||||||||||
Medical condition: Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2024-000361-24 | Sponsor Protocol Number: C4591054 | Start Date*: 2024-10-30 | |||||||||||||||||||||
Sponsor Name:BioNTech SE | |||||||||||||||||||||||
Full Title: A Phase 2/3 Protocol To Investigate the Safety, Tolerability, and Immunogenicity Of BNT162b2 RNA-Based Vaccine Candidates For SARS-CoV-2 New Variants in Healthy Individuals | |||||||||||||||||||||||
Medical condition: Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2024-000001-33 | Sponsor Protocol Number: C4591048 | Start Date*: 2024-02-07 | |||||||||||||||||||||
Sponsor Name:BioNTech SE | |||||||||||||||||||||||
Full Title: A Master Phase 1/2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of Variant-Adapted BNT162b2 RNA-Based Vaccine Candidate(s) in Healthy Children | |||||||||||||||||||||||
Medical condition: Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003458-22 | Sponsor Protocol Number: BNT162-17 | Start Date*: 2021-10-04 | |||||||||||||||||||||
Sponsor Name:BioNTech SE | |||||||||||||||||||||||
Full Title: A Phase II trial to evaluate the safety and immunogenicity of SARS-CoV-2 monovalent and multivalent RNA-based vaccines in healthy subjects | |||||||||||||||||||||||
Medical condition: Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-000843-33 | Sponsor Protocol Number: FERMIN | Start Date*: 2021-04-23 | |||||||||||||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | |||||||||||||||||||||||
Full Title: Fenofibrate as a Metabolic Intervention for Coronavirus Disease 2019 (COVID-19): A randomized controlled trial (FERMIN trial) | |||||||||||||||||||||||
Medical condition: Coronavirus disease-19 | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GR (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001747-21 | Sponsor Protocol Number: ISPUP2020CT1 | Start Date*: 2020-07-06 | |||||||||||
Sponsor Name:Instituto de Saúde Pública Universidade Porto | |||||||||||||
Full Title: Impact of Montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): an investigator-initiated open labelled randomized controlled pragmatic trial | |||||||||||||
Medical condition: Novel coronavirus pneumonia (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001345-38 | Sponsor Protocol Number: UNIKINON-01/HOPE | Start Date*: 2020-04-02 | |||||||||||
Sponsor Name:Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | |||||||||||||
Full Title: CHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS SARS-CoV-2 (COVID-19): THE HOPE OPEN-LABEL, NON-RANDOMIZED CLINICAL TRIAL | |||||||||||||
Medical condition: Possible prevention of pneumonia from SARS-CoV-2 in patients staying home and improving symptoms of SARS-CoV-2 pneumonia in patients treated in hospital | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001456-18 | Sponsor Protocol Number: AZIQUINE-ICU-25032020 | Start Date*: 2020-04-09 |
Sponsor Name:Nadační fond Donatio intensivistam | ||
Full Title: Azithromycin added to Hydrochloroquine in Patients Admitted to Intensive Care due to Coronavirus Disease 2019 (COVID-19) - Randomised Controlled Trial, phase III | ||
Medical condition: Severe COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-002542-16 | Sponsor Protocol Number: INSIGHT013 | Start Date*: 2020-09-30 | |||||||||||
Sponsor Name:Office of Sponsored Projects, Regents of the University of Minnesota | |||||||||||||
Full Title: An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the... | |||||||||||||
Medical condition: COVID-19 (SARS-CoV-2) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) DK (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001039-29 | Sponsor Protocol Number: ESCAPE | Start Date*: 2020-04-01 | |||||||||||
Sponsor Name:HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS | |||||||||||||
Full Title: EFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH: THE ESCAPE CLINICAL TRIAL | |||||||||||||
Medical condition: Organ dysfunction by the novel SARS-Cov-2 virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002211-21 | Sponsor Protocol Number: SGS.1656.201 | Start Date*: 2020-07-31 | |||||||||||
Sponsor Name:St George Street Capital Ltd | |||||||||||||
Full Title: A Phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in diabetic patients hospitalised with suspected or confirmed COVID-19. The ARCA... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001558-23 | Sponsor Protocol Number: COFID19-AIFA17/2020 | Start Date*: 2020-04-09 | |||||||||||
Sponsor Name:ASUR (Azienda Sanitaria Unica Regionale) Marche | |||||||||||||
Full Title: Hydroxychloroquine sulfate early administration in symptomatic out of hospital COVID-19 positive patients. Hydro-Stop-COVID19 Trial | |||||||||||||
Medical condition: Emerging disease (COVID-19) due to a novel coronavirus (named SARS-CoV-2 latter) started in Wuhan, China and rapidly spread in China and outside and has been declared pandemic by WHO on March 12th ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001805-21 | Sponsor Protocol Number: RA486120 | Start Date*: 2020-05-15 |
Sponsor Name:University Hospital Coventry & Warwickshire | ||
Full Title: Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19 | ||
Medical condition: Sars-Cov-2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001953-36 | Sponsor Protocol Number: GC2005 | Start Date*: 2020-05-08 | ||||||||||||||||
Sponsor Name:Instituto Grifols, S.A | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin® plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects w... | ||||||||||||||||||
Medical condition: Patients with Coronavirus Disease (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001696-32 | Sponsor Protocol Number: GC2004 | Start Date*: 2020-05-08 | ||||||||||||||||
Sponsor Name:Instituto Grifols, S.A | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alo... | ||||||||||||||||||
Medical condition: Patients with Mild to Moderate Coronavirus Disease (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001565-37 | Sponsor Protocol Number: PrEP_COVID | Start Date*: 2020-04-03 |
Sponsor Name:ISGlobal | ||
Full Title: PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE FOR HIGH-RISK HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC (PrEP_COVID): A UNICENTRIC, DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL. | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001958-36 | Sponsor Protocol Number: SDX_01 | Start Date*: 2022-08-29 |
Sponsor Name:Corporativo de Servicios Médicos Especializados S.A de C.V V (Centro Médico del Noroeste) | ||
Full Title: Endothelial protection in convalecent COVID-19 patients. The effect of Sulodexide on serum levels of biomarkers for endothelial dysfunction. A prospective, randomized, placebo-controlled, investiga... | ||
Medical condition: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by coronavirus 2 (SARS-CoV-2) and, thus, being a novel cause of sepsis and the the poor outcome of patients with sepsis was relat... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000864-32 | Sponsor Protocol Number: NL76798.078.21 | Start Date*: 2021-03-29 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: A Phase I-II study of virus neutralizing antibodies against SARS-CoV-2. A focus on convalescent plasma and hyperimmune anti-SARS-CoV2 immunoglobulines | |||||||||||||
Medical condition: COVID-19 or protective effect against in B-cell depleted patients or vaccination non-responders | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004928-42 | Sponsor Protocol Number: REM-ENY-01 | Start Date*: 2020-10-12 | |||||||||||
Sponsor Name:Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium | |||||||||||||
Full Title: Open-label study to assess the safety of REMdesivir-HU as Eligible Novel therapY for moderate and severe Covid-19 patients | |||||||||||||
Medical condition: SARS-CoV-2 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
